Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model.

Lewis JS, McCarthy DW, McCarthy TJ, Fujibayashi Y, Welch MJ.

J Nucl Med. 1999 Jan;40(1):177-83.

2.

Retention of the radiotracers 64Cu-ATSM and 64Cu-PTSM in human and murine tumors is influenced by MDR1 protein expression.

Liu J, Hajibeigi A, Ren G, Lin M, Siyambalapitiyage W, Liu Z, Simpson E, Parkey RW, Sun X, Oz OK.

J Nucl Med. 2009 Aug;50(8):1332-9. doi: 10.2967/jnumed.109.061879. Epub 2009 Jul 17.

3.

Monitoring the effect of mild hyperthermia on tumour hypoxia by Cu-ATSM PET scanning.

Myerson RJ, Singh AK, Bigott HM, Cha B, Engelbach JA, Kim J, Lamoreaux WT, Moros E, Novak P, Sharp TL, Straube W, Welch MJ, Xu M.

Int J Hyperthermia. 2006 Mar;22(2):93-115.

PMID:
16754595
4.

Comparison of 18F-fluoroazomycin-arabinofuranoside and 64Cu-diacetyl-bis(N4-methylthiosemicarbazone) in preclinical models of cancer.

Valtorta S, Belloli S, Sanvito F, Masiello V, Di Grigoli G, Monterisi C, Fazio F, Picchio M, Moresco RM.

J Nucl Med. 2013 Jul;54(7):1106-12. doi: 10.2967/jnumed.112.111120. Epub 2013 May 22.

5.

Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models.

O'Donoghue JA, Zanzonico P, Pugachev A, Wen B, Smith-Jones P, Cai S, Burnazi E, Finn RD, Burgman P, Ruan S, Lewis JS, Welch MJ, Ling CC, Humm JL.

Int J Radiat Oncol Biol Phys. 2005 Apr 1;61(5):1493-502.

PMID:
15817355
6.

Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone).

Yuan H, Schroeder T, Bowsher JE, Hedlund LW, Wong T, Dewhirst MW.

J Nucl Med. 2006 Jun;47(6):989-98.

7.

Nitroimidazole conjugates of bis(thiosemicarbazonato)64Cu(II) - Potential combination agents for the PET imaging of hypoxia.

Bonnitcha PD, Bayly SR, Theobald MB, Betts HM, Lewis JS, Dilworth JR.

J Inorg Biochem. 2010 Feb;104(2):126-35. doi: 10.1016/j.jinorgbio.2009.10.009. Epub 2009 Oct 24.

8.

The influence of tumor oxygenation on hypoxia imaging in murine squamous cell carcinoma using [64Cu]Cu-ATSM or [18F]Fluoromisonidazole positron emission tomography.

Matsumoto K, Szajek L, Krishna MC, Cook JA, Seidel J, Grimes K, Carson J, Sowers AL, English S, Green MV, Bacharach SL, Eckelman WC, Mitchell JB.

Int J Oncol. 2007 Apr;30(4):873-81.

PMID:
17332926
9.

Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer.

Dence CS, Ponde DE, Welch MJ, Lewis JS.

Nucl Med Biol. 2008 Aug;35(6):713-20. doi: 10.1016/j.nucmedbio.2008.06.001.

10.

Investigation into 64Cu-labeled Bis(selenosemicarbazone) and Bis(thiosemicarbazone) complexes as hypoxia imaging agents.

McQuade P, Martin KE, Castle TC, Went MJ, Blower PJ, Welch MJ, Lewis JS.

Nucl Med Biol. 2005 Feb;32(2):147-56.

PMID:
15721760
11.

Cardiac hypoxia imaging: second-generation analogues of 64Cu-ATSM.

Handley MG, Medina RA, Mariotti E, Kenny GD, Shaw KP, Yan R, Eykyn TR, Blower PJ, Southworth R.

J Nucl Med. 2014 Mar;55(3):488-94. doi: 10.2967/jnumed.113.129015. Epub 2014 Jan 13.

12.

A comparison of the behavior of (64)Cu-acetate and (64)Cu-ATSM in vitro and in vivo.

Hueting R, Kersemans V, Cornelissen B, Tredwell M, Hussien K, Christlieb M, Gee AD, Passchier J, Smart SC, Dilworth JR, Gouverneur V, Muschel RJ.

J Nucl Med. 2014 Jan;55(1):128-34. doi: 10.2967/jnumed.113.119917. Epub 2013 Dec 12.

13.

Enhancing targeted radiotherapy by copper(II)diacetyl- bis(N4-methylthiosemicarbazone) using 2-deoxy-D-glucose.

Aft RL, Lewis JS, Zhang F, Kim J, Welch MJ.

Cancer Res. 2003 Sep 1;63(17):5496-504.

14.

Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation.

Lewis JS, Sharp TL, Laforest R, Fujibayashi Y, Welch MJ.

J Nucl Med. 2001 Apr;42(4):655-61.

15.

In vitro and in vivo evaluations of a hydrophilic 64Cu-bis(thiosemicarbazonato)-glucose conjugate for hypoxia imaging.

Bayly SR, King RC, Honess DJ, Barnard PJ, Betts HM, Holland JP, Hueting R, Bonnitcha PD, Dilworth JR, Aigbirhio FI, Christlieb M.

J Nucl Med. 2008 Nov;49(11):1862-8. doi: 10.2967/jnumed.108.054015. Epub 2008 Oct 16.

16.

Cell line-dependent differences in uptake and retention of the hypoxia-selective nuclear imaging agent Cu-ATSM.

Burgman P, O'Donoghue JA, Lewis JS, Welch MJ, Humm JL, Ling CC.

Nucl Med Biol. 2005 Aug;32(6):623-30.

PMID:
16026709
17.

Copper-64-diacetyl-bis(N(4)-methylthiosemicarbazone) pharmacokinetics in FaDu xenograft tumors and correlation with microscopic markers of hypoxia.

McCall KC, Humm JL, Bartlett R, Reese M, Carlin S.

Int J Radiat Oncol Biol Phys. 2012 Nov 1;84(3):e393-9. doi: 10.1016/j.ijrobp.2012.05.005. Epub 2012 Jun 23.

18.

Basic characterization of 64Cu-ATSM as a radiotherapy agent.

Obata A, Kasamatsu S, Lewis JS, Furukawa T, Takamatsu S, Toyohara J, Asai T, Welch MJ, Adams SG, Saji H, Yonekura Y, Fujibayashi Y.

Nucl Med Biol. 2005 Jan;32(1):21-8. Erratum in: Nucl Med Biol. 2005 Jul;32(5):559.

PMID:
15691658
19.

In vitro and in vivo evaluation of bifunctional bisthiosemicarbazone 64Cu-complexes for the positron emission tomography imaging of hypoxia.

Bonnitcha PD, Vāvere AL, Lewis JS, Dilworth JR.

J Med Chem. 2008 May 22;51(10):2985-91. doi: 10.1021/jm800031x. Epub 2008 Apr 17.

20.

Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone).

Dehdashti F, Grigsby PW, Lewis JS, Laforest R, Siegel BA, Welch MJ.

J Nucl Med. 2008 Feb;49(2):201-5. doi: 10.2967/jnumed.107.048520. Epub 2008 Jan 16.

Supplemental Content

Support Center